Enhertu approved for PBS for those with HER2 metastatic breast cancer

BCNA welcomes the listing of Enhertu (trastuzumab deruxtecan) on the Pharmaceutical Benefits Scheme (PBS) for those with metastatic breast cancer  

BCNA supported the process for Enhertu to be considered for listing on the PBS and we welcome the government subsidy for this exciting new drug.

“This is a significant step towards achieving greater equity of access for a life prolonging drug like Enhertu,” says BCNA director Policy, Advocacy & Support Services Vicki Durston.

Enhertu is listed on the PBS to treat patients who have been diagnosed with metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer as of 1 November.

Read the Australian Government’s announcement about Enhertu: New treatment for women battling aggressive breast cancer.

If you have any questions about Enhertu we encourage you to speak to your treating team.